CMS’ upcoming ACCESS payment model is being billed as a turning point in how chronic care is reimbursed and managed — aiming to tie payments to patient outcomes and expand the use of digital tools.

Innovative financing and reimbursement models can improve access to cell and gene therapies, addressing cost barriers and improving patient outcomes, said Joe DePinto, MBA, of McKesson. Innovative ...

The CMS CGT Access Model involves 33 states, D.C., and Puerto Rico, focusing on sickle cell disease treatments for Medicaid beneficiaries. Outcomes-based contracts with manufacturers ensure discounts ...

WASHINGTON, DC: Centers for Medicare and Medicaid Services Administrator Chiquita Brooks-LaSure announced on December 5th that the manufacturers of the sickle cell disease gene therapies, Lyfgenia and ...

LAS CRUCES, NEW MEXICO / ACCESS Newswire / December 2, 2025 / Following CMS's announcement of the new ACCESS Model (Advancing Chronic Care with Effective, Scalable Solutions), Electronic Caregiver, ...

For decades, chronic disease management in Medicare has been hampered by a fee-for-service payment system that rewards volume and activity rather than true clinical improvement. This model created ...